Skip to main content

Table 4 Comparison of three AKI biomarker study characteristics

From: Urinary cell cycle arrest biomarkers and chitinase 3-like protein 1 (CHI3L1) to detect acute kidney injury in the critically ill: a post hoc laboratory analysis on the FINNAKI cohort

 

Sapphire [5]

BAKI-I [8]

FINNAKI-CHI3L1 (present study)

n

728

181

660

Biomarker studied

TIMP-2•IGFBP7

CHI3L1

CHI3L1

TIMP-2•IGFBP7

Centers

Multi

Single

Multi

Age (years)

64 (53, 73)

60 (51, 70)

64 (53, 73)

Male gender (%)

62

63

62

Baseline Cr (μmol/L)

80

58

82

Diabetes (%)

29

7.2

21.2

SAPS II

NA

NA

38 (29, 49)

APACHE III

69 (51, 90)

NA

NA

SOFA

NA

9 (7, 11)

7 (4,9)

Emergency department

NA

41.4%

41.2%

Medical ICU admission (%)

31.0

59.7

70.9

AKI stages 2–3 < 12 h (%)

14.0

3.3

NA

AKI stages 2–3 < 24 h (%)

NA

4.9

7.4

AUC-ROC for AKI stages 2–3 < 12 h

0.80

0.79

NA

AUC-ROC for AKI stages 2–3 < 24 h

NA

0.72

uCHI3L1, 0.67

NephroCheck, 0.67